Core Viewpoint - Recent developments for Lifan Pharmaceutical (stock code: 003020) focus on product procurement progress and market performance, with three core products expected to enhance sales and market share through national procurement [1] Group 1: Recent Events - Product Procurement Selection: On February 10, 2026, Lifan Pharmaceutical announced that its three products—Nifedipine Controlled-Release Tablets, Venlafaxine Hydrochloride Sustained-Release Tablets, and Trimethoprim Sustained-Release Tablets—are proposed for selection in the national procurement program, which could significantly boost sales and market share [2] - New Drug Application Progress: On the same day, the application for the raw material drug Finerenone was accepted by the National Medical Products Administration, aimed at treating chronic kidney disease related to type 2 diabetes, currently under review [2] Group 2: Stock Performance - Stock Price Movement: Over the past week (February 5 to 11), the stock price fluctuated by 0.84%, with a high of 26.99 yuan on February 6 and a low of 26.22 yuan on February 9. The closing price on February 11 was 26.53 yuan, with a single-day increase of 0.53% and a trading volume of 30.08 million yuan [3] - Capital Flow Situation: On February 11, there was a net outflow of 1.7835 million yuan from institutional investors, while retail investors showed a net inflow, indicating overall stable liquidity [3] Group 3: Sector Performance - Sector Comparison: During the same period, the pharmaceutical and biotechnology sector declined by 0.50%, while Lifan Pharmaceutical's stock performance was slightly better than the sector average [4] Group 4: Institutional Insights - Strategic Transformation Analysis: On February 6, 2026, Morningstar Research noted that Lifan Pharmaceutical is focusing on high-barrier areas such as osmotic pump controlled-release technology and narcotic drugs, with core products like Methylphenidate Hydrochloride Sustained-Release Tablets already on the market. However, short-term performance may experience fluctuations, necessitating attention to new drug volume and balancing R&D investments [5]

Core Viewpoint - The company has received a notice of acceptance for the raw material drug Fenofibrate from the National Medical Products Administration, indicating that the product has entered the registration review stage [1] Group 1 - The acceptance of the raw material drug application signifies that the product is now in the registration review phase [1] - The approval of Fenofibrate would further enrich the company's raw material drug product pipeline [1] - The impact on the company's recent performance is not expected to be significant [1]

Core Viewpoint - The company has received a notice from the National Medical Products Administration regarding the acceptance of the marketing application for Finerenone, a novel non-steroidal selective mineralocorticoid receptor antagonist (MRA) [1] Group 1 - Finerenone is indicated for adult patients with chronic kidney disease associated with type 2 diabetes, aimed at reducing the risk of sustained decline in eGFR and end-stage renal disease [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development and potential market entry [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) [1] - The formulation is intended for adult patients with chronic kidney disease associated with type 2 diabetes, aiming to reduce the risk of sustained decline in eGFR and end-stage renal disease [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received a notice of acceptance for the listing application of Finerenone raw material from the National Medical Products Administration, indicating progress in its product development pipeline [1] Group 1: Product Information - Finerenone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) intended for use in adult patients with chronic kidney disease associated with type 2 diabetes, specifically for those with an estimated glomerular filtration rate (eGFR) between 25 to 75 ml/min/1.73m² and albuminuria [1] - The formulation aims to reduce the risk of sustained decline in eGFR and end-stage renal disease [1] Group 2: Market Context - The application pertains to a generic chemical raw material used in already marketed formulations within the country [1] - Among the companies that have registered this raw material, five have an "A" status, indicating approval for use in marketed formulations, while the rest are marked as "I," meaning they have not yet passed the joint review and approval with the formulations [1]